New drug candidate GL-0719 enters first human safety trials for rare blood disorder
Disease control
Recruiting now
This early-stage study tests a new drug called GL-0719 for the first time in humans. It aims to check the drug's safety and how the body processes it in healthy adults and in people with cold agglutinin disease, a rare condition where the immune system attacks red blood cells in …
Phase: PHASE1 • Sponsor: Gliknik Inc. • Aim: Disease control
Last updated May 01, 2026 15:59 UTC